L & S Advisors Inc Has $7.74 Million Position in Boston Scientific Corporation $BSX

L & S Advisors Inc lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 13.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 72,090 shares of the medical equipment provider’s stock after acquiring an additional 8,525 shares during the period. L & S Advisors Inc’s holdings in Boston Scientific were worth $7,743,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after buying an additional 3,932 shares in the last quarter. MRA Advisory Group acquired a new position in shares of Boston Scientific during the second quarter worth approximately $273,000. Bank of New Hampshire grew its stake in shares of Boston Scientific by 552.0% during the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd increased its holdings in shares of Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. acquired a new position in shares of Boston Scientific during the second quarter valued at $1,133,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 0.8%

Shares of BSX stock opened at $104.99 on Friday. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $99.81 and a 200-day moving average of $102.56. The firm has a market cap of $155.65 billion, a P/E ratio of 56.15, a PEG ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the company earned $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Thursday, October 23rd. Leerink Partners lifted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $123.77.

Insider Buying and Selling

In other news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 175,782 shares of company stock valued at $17,742,314. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.